Trailing-twelve-month (TTM) revenue is $2.23 Billion with a year-over-year growth of (27.19%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $1,016,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $678,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-20 |
| Q1 FY2026Period ended 2026-03-31 | $389,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-01 |
| Q2 FY2026Period ended 2026-06-30 | $145,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-31 |
| TTM revenue | $2,228,000,000 |
Current P/S: $53,808,149,460 market capitalization ÷ $2,228,000,000 TTM revenue = 24.15x.
Market capitalization source: FMP quote. Quote observed 2026-09-09T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $145.00M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-09T20:00:01.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-30 · USD | FY20212021-12-30 · USD | FY20222022-12-30 · USD | FY20232023-12-30 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Collaboration Arrangement | N/A | N/A | N/A | N/A | $12M | N/A |
| Grant | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Europe | N/A | $6.8B | $6.8B | $1.4B | $598M | $53M |
| Rest Of The World | $39M | $5.4B | $7.3B | $3.6B |
$2.23B
$2.23 Billion
(27.19%)
vs. $3.06B a year ago (TTM)
+19.33%
5 Year compound annual growth rate
1 Year
(27.19%)
3 Year
(40.44%)
5 Year
+19.33%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $1.94B | ($1.25B) | (39.23%) |
| 2024 | $3.20B | ($3.65B) | (53.29%) |
| 2023 | $6.85B | ($12.03B) | (63.72%) |
| 2022 | $18.88B | +$1.14B | +6.42% |
| 2021 | $17.74B | +$16.93B | +2107.63% |
| 2020 |
TTM Growth
(27.19%)
3-Year CAGR
(40.44%)
5-Year CAGR
(19.73%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 29 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-09T20:00:01.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| $37M |
| N/A |
| Messenger RNA (mRNA) Medicines | $803M | $18.5B | $19.3B | $6.8B | N/A | N/A |
|---|
| Product Sales | N/A | N/A | N/A | N/A | $4.5B | $3.3B |
|---|
| $810M |
| $603M |
| UNITED STATES | $765M | $6.2B | $5.2B | $1.9B | $1.8B | $1.2B |
|---|
| $803.39M |
| +$743.19M |
| +1234.34% |
| 2019 | $60.21M | ($74.86M) | (55.42%) |
| 2018 | $135.07M | ($70.76M) | (34.38%) |
| 2017 | $205.82M | +$97.43M | +89.88% |
